ArticleJournal of the National Cancer Institute2023

Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer.

No numbers read from the abstract.

Not cited yet